EP1534335A4

Fcgammariib-specific antibodies and methods of use thereof

Abstract

This record has no abstract on file.

Term

Term ended

Projected expiry passed 14 August 2023, 3.1 years ago.

Every citation, both ways

Citations
Document	Relation	Office	Category	Cited during	Relevant claims
WO0042072A2	Cites	World Intellectual Property Organization (WIPO)	Y	Search report	31,32,78,79,104-107
EP0332865A2	Cites	European Patent Office (EPO)	Y	Search report	25-29
EP0629703A2	Cites	European Patent Office (EPO)	Y	Search report	19,20,25,26,60-64,77-79,93-95
EP0953639A1	Cites	European Patent Office (EPO)	Y	Search report	100-103
WO9919362A1	Cites	World Intellectual Property Organization (WIPO)	Y	Search report	60-64,80
WO9941285A1	Cites	World Intellectual Property Organization (WIPO)	Y	Search report	17,18,27,28,78,79,98,99
WO9958572A1	Cites	World Intellectual Property Organization (WIPO)	XY	Search report	1-8,16,22,24,25,30,39,42,44-50,65,73-76,81-90
WO9958572A	Cites	World Intellectual Property Organization (WIPO)	–	–	–
WO9941285A	Cites	World Intellectual Property Organization (WIPO)	–	–	–
EP0629703A	Cites	European Patent Office (EPO)	–	–	–
EP0332865A	Cites	European Patent Office (EPO)	–	–	–
WO0042072A	Cites	World Intellectual Property Organization (WIPO)	–	–	–
WO9919362A	Cites	World Intellectual Property Organization (WIPO)	–	–	–
EP0953639A	Cites	European Patent Office (EPO)	–	–	–
WEINRICH V ET AL: "Epitope mapping of new monoclonal antibodies recognizing distinct human FcRII (CD32) isoforms", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, vol. 15, no. 2, April 1996 (1996-04-01), pages 109 - 116, XP009046826, ISSN: 0272-457X	Non-patent	–	–	Search report	–
MICKLEM K J ET AL: "Different isoforms of human FcRII distinguished by CDw32 antibodies.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 MAR 1990, vol. 144, no. 6, 15 March 1990 (1990-03-15), pages 2295 - 2303, XP002378174, ISSN: 0022-1767	Non-patent	–	–	Search report	–
KURLANDER R J ET AL: "Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice.", THE JOURNAL OF CLINICAL INVESTIGATION. JUN 1986, vol. 77, no. 6, June 1986 (1986-06-01), pages 2010 - 2018, XP002378175, ISSN: 0021-9738	Non-patent	–	–	Search report	–
FANGER M W ET AL: "Production and Use of Anti-FcR Bispecific Antibodies", IMMUNOMETHODS, vol. 4, no. 1, 1 February 1994 (1994-02-01), pages 72 - 81, XP000608179, ISSN: 1058-6687	Non-patent	–	–	Search report	–
SCHUNA A A ET AL: "New drugs for the treatment of rheumatoid arthritis", AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, vol. 57, no. 3, 1 February 2000 (2000-02-01), pages 225 - 237, XP000944489, ISSN: 1079-2082	Non-patent	–	–	Search report	–
XU YUANYUAN ET AL: "Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 JUL 2003, vol. 171, no. 2, 15 July 2003 (2003-07-15), pages 562 - 568, XP002378176, ISSN: 0022-1767	Non-patent	–	–	Search report	–

75 members in 16 offices

This recordMember, by publication datePriority claim6 more offices are in the list below

Priority claims3

Priority claims
Document	Office	Kind	Date
403266P	United States of America	–	2002-08-14
40326602	United States of America	P	2002-08-14
0325399	United States of America	W	2003-08-14

Members75

Family members, oldest first
Document	Office	Kind
CA2495251A1	Canada	A1	2004-02-26
WO2004016750A2	World Intellectual Property Organization (WIPO)	A2	2004-02-26
AU2003262650A1	Australia	A1	2004-03-03
US2004185045A1	United States of America	A1	2004-09-23
WO2004016750A3	World Intellectual Property Organization (WIPO)	A3	2005-03-17
EP1534335A2	European Patent Office (EPO)	A2	2005-06-01
US2005215767A1	United States of America	A1	2005-09-29
US2005260213A1	United States of America	A1	2005-11-24
AU2005247301A1	Australia	A1	2005-12-08
CA2563314A1	Canada	A1	2005-12-08
WO2005115452A2	World Intellectual Property Organization (WIPO)	A2	2005-12-08
JP2006506977A	Japan	A	2006-03-02
WO2005115452A9	World Intellectual Property Organization (WIPO)	A9	2006-04-06
HK1079979A	Hong Kong, China	A	2006-04-21
HK1079979A1	Hong Kong, China	A1	2006-04-21
WO2005115452A3	World Intellectual Property Organization (WIPO)	A3	2006-05-26
CA2590935A1	Canada	A1	2006-06-22
WO2006066078A2	World Intellectual Property Organization (WIPO)	A2	2006-06-22
EP1534335A4This record	European Patent Office (EPO)	A4	2006-07-05
US2006177439A1	United States of America	A1	2006-08-10
WO2006066078A3	World Intellectual Property Organization (WIPO)	A3	2006-10-19
EP1747237A2	European Patent Office (EPO)	A2	2007-01-31
IL178593A0	Israel	A0	2007-02-11
KR20070038453A	Republic of Korea	A	2007-04-10
MXPA06011796A	Mexico	A	2007-05-07
CN101001872A	China	A	2007-07-18
EP1833849A2	European Patent Office (EPO)	A2	2007-09-19
JP2007532139A	Japan	A	2007-11-15
EP1747237A4	European Patent Office (EPO)	A4	2008-05-21
US7425619B2	United States of America	B2	2008-09-16
US7425620B2	United States of America	B2	2008-09-16
US2009017023A1	United States of America	A1	2009-01-15
US2009017026A1	United States of America	A1	2009-01-15
US2009017027A1	United States of America	A1	2009-01-15
US2009053218A1	United States of America	A1	2009-02-26
US2009074771A1	United States of America	A1	2009-03-19
US2009076251A1	United States of America	A1	2009-03-19
US2009092610A1	United States of America	A1	2009-04-09
EP1833849A4	European Patent Office (EPO)	A4	2009-08-05
AU2003262650B2	Australia	B2	2009-10-29
JP4459810B2	Japan	B2	2010-04-28
AU2005247301B2	Australia	B2	2011-08-18
SG173322A1	Singapore	A1	2011-08-29
EP2371389A2	European Patent Office (EPO)	A2	2011-10-05
US8044180B2	United States of America	B2	2011-10-25
EP1534335B1	European Patent Office (EPO)	B1	2011-12-07
AT536188T	Austria	T	2011-12-15
ATE536188T1	Austria	T1	2011-12-15
US2012009186A1	United States of America	A1	2012-01-12
DK1534335T3	Denmark	T3	2012-02-13
PT1534335E	Portugal	E	2012-02-28
EP2371389A3	European Patent Office (EPO)	A3	2012-04-18
US8187593B2	United States of America	B2	2012-05-29
ES2381617T3	Spain	T3	2012-05-30
US8193318B2	United States of America	B2	2012-06-05
US8530627B2	United States of America	B2	2013-09-10
IL228068A0	Israel	A0	2013-09-30
IL228069A0	Israel	A0	2013-09-30
JP5367982B2	Japan	B2	2013-12-11
CA2590935C	Canada	C	2014-09-30
US8946387B2	United States of America	B2	2015-02-03
US8968730B2	United States of America	B2	2015-03-03
EP1534335B2	European Patent Office (EPO)	B2	2015-06-24
IL166843A	Israel	A	2015-07-30
DK1534335T4	Denmark	T4	2015-10-05
US2015344574A1	United States of America	A1	2015-12-03
US2015344575A1	United States of America	A1	2015-12-03
EP1534335B9	European Patent Office (EPO)	B9	2016-01-13
ES2381617T5	Spain	T5	2016-02-24
ES2381617T9	Spain	T9	2016-03-10
IL178593A	Israel	A	2016-04-21
IL228068A	Israel	A	2017-01-31
IL228069A	Israel	A	2017-01-31
CA2495251C	Canada	C	2018-03-06
US2020131265A1	United States of America	A1	2020-04-30

105 legal events, as 17 offices reported them to INPADOC

Over the term

Point at a mark for the event

Events

Legal events, newest first
	Event	Code	Office
2023-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2023-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2023-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2023-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2023-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2023-10-15	ExpiryMK07	MK07	AT
2023-09-29	Patent expired because of reaching the maximum lifetime of a patentExpiredMK	MK	BE
2023-09-27	Patent expiredExpiredMK9A	MK9A	IE
2023-09-06	Patent expired after termination of 20 yearsExpiredPE20	PE20	GB
2023-08-25	Announcement of lapse in spainLapsedFD2A	FD2A	ES
2023-08-21	Ep patent expiredExpiredEUP	EUP	DK
2023-08-16	Patent expired because of reaching the maximum lifetime of a patentExpiredMK	MK	NL
2023-08-15	Patent ceasedCeasedPL	PL	CH
2023-08-14	Expiry of rightR071	R071	DE
2022-12-30	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-11-30	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-11-30	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-11-30	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-09-30	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-07-29	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-07-29	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-07-29	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-07-29	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-07-29	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-06-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2019-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2018-07-12	Fee paymentPLFP	PLFP	FR
2017-07-14	Fee paymentPLFP	PLFP	FR
2017-05-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2017-05-31	Patent reinstated in contracting state [announced from national office to epo]PGRI	PGRI	EP
2016-07-15	Name/firm changedPFA	PFA	CH
2016-07-12	Fee paymentPLFP	PLFP	FR
2016-03-18	Amendment of standard patent following opposition or revocation proceedings in the designated patent office (acc. sect 43 patent ordinance)OppositionAM43	AM43	HK
2016-02-24	Patent modifiedDC2A	DC2A	ES
2015-12-17	Ep patent validated in greeceEP	EP	GR
2015-11-15	Publication of translation of european patent specificationUEP	UEP	AT
2015-11-04	Translation for ep filed (entry of ep into country)FP	FP	NL
2015-10-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2015-10-27	Patent application has lapsedLapsedNAV	NAV	SE
2015-10-05	Amended ep patent with danish claimsT4	T4	DK
2015-06-30	Maintained in amend formAELC	AELC	CH
2015-06-29	Fee paymentPLFP	PLFP	FR
2015-06-24	Patent maintained in amended form27A	27A	EP
2015-06-24	Designated contracting statesAK	AK	EP
2015-06-24	Epo decision maintaining patent in amended form now finalR102	R102	DE
2015-05-22	Patent maintained in amended formORIGINAL CODE: 0009272PUAH	PUAH	EP
2015-05-22	Information on the status of an ep patent application or granted ep patentGrantedSTATUS: PATENT MAINTAINED AS AMENDEDSTAA	STAA	EP
2014-10-02	Observations filed by third partiesORIGINAL CODE: EPIDOSNTIPATPAC	TPAC	EP
2014-08-08	Opposition withdrawnWithdrawnORIGINAL CODE: 0009264PLBP	PLBP	EP
2014-06-06	Opposition withdrawnWithdrawnORIGINAL CODE: 0009264PLBP	PLBP	EP
2014-05-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-06-24	Reply of patent proprietor to notice(s) of opposition receivedOppositionORIGINAL CODE: EPIDOSNOBS3PLBB	PLBB	EP
2013-04-23	Information modified related to communication of a notice of opposition and request to file observations + time limitOppositionORIGINAL CODE: EPIDOSCOBS2PLAF	PLAF	EP
2013-03-29	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-02-22	Information modified related to communication of a notice of opposition and request to file observations + time limitOppositionORIGINAL CODE: EPIDOSCOBS2PLAF	PLAF	EP
2012-11-29	Opposition filed against patentOppositionR026	R026	DE
2012-10-31	Opposition filed (corrected)OppositionR26	R26	EP
2012-10-31	Opposition filed (corrected)OppositionR26	R26	EP
2012-10-17	Opposition filed (corrected)OppositionR26	R26	EP
2012-10-17	Opposition filed (corrected)OppositionR26	R26	EP
2012-10-15	Notice of opposition and request to file observation + time limit sentOppositionORIGINAL CODE: EPIDOSNOBS2PLAX	PLAX	EP
2012-10-12	Standard patents granted in hong kongGrantedGR	GR	HK
2012-10-10	Opposition filedOpposition26	26	EP
2012-09-28	Opposition data, opponent's data or that of the opponent's representative modifiedOppositionORIGINAL CODE: 0009299OPPOPLAB	PLAB	EP
2012-09-14	Opposition data, opponent's data or that of the opponent's representative modifiedOppositionORIGINAL CODE: 0009299OPPOPLAB	PLAB	EP
2012-09-14	Opposition filedOppositionORIGINAL CODE: 0009260PLBI	PLBI	EP
2012-09-07	Opposition filedOppositionORIGINAL CODE: 0009260PLBI	PLBI	EP
2012-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-06-29	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-06-28	Filing of the translation of the text of european patentsAG4A	AG4A	HU
2012-05-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-05-30	Definitive protectionFG2A	FG2A	ES
2012-05-29	Ep patent validated in greeceEP	EP	GR
2012-03-15	New agentNV	NV	CH
2012-03-13	Translation of granted ep patentGrantedTRGR	TRGR	SE
2012-03-01	Dpma publication of mentioned ep patent grantGrantedR096	R096	DE
2012-02-29	Translation filed for an european patent granted for nl, confirming art. 52 par. 1 or 6 of the patents act 1995GrantedT3	T3	NL
2012-02-28	Translation is availableAVAILABILITY OF NATIONAL TRANSLATIONSC4A	SC4A	PT
2012-02-20	Ep patent valid in romaniaEPE	EPE	RO
2012-02-13	Ep patent with danish claimsT3	T3	DK
2012-01-04	European patents granted designating irelandGrantedFG4D	FG4D	IE
2011-12-15	European patent takes effect as a national patent in ch/liEP	EP	CH
2011-12-07	Designated contracting statesAK	AK	EP
2011-12-07	European patent grantedGrantedFG4D	FG4D	GB
2011-11-04	(expected) grantORIGINAL CODE: 0009210GRAA	GRAA	EP
2011-11-03	Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS	GRAS	EP
2011-06-01	Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP	GRAP	EP
2007-02-28	First examination report despatched17Q	17Q	EP
2006-07-05	Supplementary search report drawn up and despatchedA4	A4	EP
2006-04-21	Requests to designate patent in hong kongDE	DE	HK

Showing 100 of 105

Fcgammariib-specific antibodies and methods of use thereof

Abstract

Term

Priority claims3

Members75

Over the term

Events

Numbers

Titles3

Classification

Designated states27